Articles by Daniel Marsh
Regeneron Shares Slide After Melanoma Combo Misses Key Goal
Regeneron shares tumbled 11.8% in premarket trading after its melanoma drug combo missed statistical significance on progression-free survival versus Keytruda.
Sunshine Biopharma Rebounds Premarket After Dilution Fears
Sunshine Biopharma shares jumped 147% in premarket trading Monday after Friday's steep fall, as traders reacted to a $6 million share-and-warrant registration and a quarterly net loss.
Compass Pathways Surges Premarket on Accelerated FDA Review for Psilocybin Drug
Compass Pathways shares surged 19.5% in premarket trading after the FDA cleared a faster review path for its COMP360 psilocybin depression treatment. The company will discuss next steps at the RBC Capital Markets conference.
Futures Dip as Oil Surge, Rising Yields Weigh; Nvidia, Retail in Focus
Dow futures slid 300 points Monday as oil stayed above $100 and Treasury yields hit 15-month highs. Nvidia's earnings and Walmart's report are in focus this week.
EchoStar Gains After FCC Greenlights $40B Spectrum Sale
EchoStar shares closed up 1.57% at $137.23 after the FCC approved its $40 billion spectrum sale to AT&T and SpaceX, but a $2.4 billion escrow requirement and weak pay-TV trends pose risks.
NextEra Energy Reportedly Nears $66 Billion Dominion Takeover
Dominion Energy shares jumped nearly 12% in pre-market trading Monday after reports that NextEra Energy is discussing a mostly stock offer near $76 per share, valuing Dominion at about $66 billion.
Riot Platforms' AI Pivot Challenges Bitcoin Investors
Riot Platforms is pivoting to AI data-center leasing, with AMD expanding to 50 MW and a nuclear power MOU. Stock trades at $23.49, Jefferies rates hold.
Li Auto Stock Plunges on Tepid Reception to L9 SUV Refresh
Li Auto shares tumbled 14% in Hong Kong after investors reacted negatively to the launch of its refreshed L9 SUV, ahead of Q1 results and amid intense EV price competition.
